When other therapies have failed, patients with metastatic prostate cancer who were treated with Jevtana (cabazitaxel) in the third-line setting experienced a toxicity profile similar to that of androgen-targeted therapies, making the chemotherapy agent a valid choice for some patients, according to results from the CARD trial.
At the European Society of Medical Oncology (ESMO) Congress 2019, CURE spoke with Dr. Arash Rezazadeh Kalebasty, a medical oncologist at Norton Cancer Institute, about the results of the trial and what Jevtana offers patients with metastatic castration-resistant prostate cancer.
Transcript:
One important outcome was the grade 3 and higher toxicities were not really very much higher than in the androgen-targeted therapy arm. I think this is very encouraging because in this population, toxicity matters. A lot of patients are elderly.
The specifics for this trial did exclude patients who were not a good candidate for chemotherapy anyway, but we have to be careful about the benefit versus risk when we offer patients chemotherapy as well.
